Johnson & Johnson Development Corporation - Organized in 1973, Johnson & Johnson Development Corporation (JJDC) is the venture capital subsidiary of Johnson & Johnson. JJDC makes private equity investments in venture funded health care companies. Portfolio companies include those in the fields of pharmaceuticals, biotechnology, medical devices, diagnostics and consumer products. JJDC also leads and manages internal investments in selected promising technologies.

InterWest
InterWest Partners (http://www.interwest.com/), founded in 1979, is a leading diversified venture capital firm focused on building long-term relationships with entrepreneurs and portfolio companies. With $1.6B capital under management, and a current investment fund of $750 million, InterWest's experienced partners bring together deep domain knowledge in Life Sciences and Information Technology. The firm's investments in Life Sciences include: ArthroCare (ARTC), Corixa (CRXA), Cor Therapeutics (CORR, acquired by Millennium Pharmaceuticals), Innovasive Devices (acquired by J+J), Inspire Pharmaceuticals (ISPH), Spinal Dynamics (acquired by Medtronic), and TheraSense (THER). InterWest Partners has offices in Menlo Park, California and Dallas, Texas.

Polaris
Established in 1996, with offices in Waltham and Seattle, Polaris has over $3 billion under management. Polaris Venture Partners have helped build numerous market leading  companies, including Accordant Health Services, Advanced Inhalation Research, Akamai Technologies, Allaire, Alnylam Pharmaceuticals, American Superconductor, Aspect Medical Systems, Avici Systems, Centra Software, Classifieds2000, deCODE genetics, Exchange.com, Matrics, Microbia, Momenta Pharmaceuticals, Paradigm Genetics, Powersoft, PSCI, SolidWorks and TransForm Pharmaceuticals.

MPM Capital
MPM Capital L.P. is a global investment management firm focused solely on life sciences investing. One of the largest investment management firms dedicated to the life sciences sector, MPM Capital has offices in Boston, San Francisco, and Munich. MPM's portfolio includes early stage start-ups as well as large capitalization public companies, representing biopharmaceutical and medical device companies, encompassing platform technology as well as product-driven opportunities. The firm manages over $2.1 billion in assets through the MPM BioVentures Family of venture capital funds and the MPM BioEquities public market funds. For additional information, please visit http://www.mpmcapital.com/.